ADC Therapeutics (ADCT) Common Equity (2021 - 2026)

ADC Therapeutics has disclosed Common Equity across 6 years of filings, most recently posting -$216.4 million for Q1 2026.

• Common Equity for Q1 2026 came in at -$216.4 million, up 9.17% year-over-year; the trailing twelve-month figure through Mar 2026 was -$216.4 million (up 9.17% YoY), and the FY2025 annual result was -$185.8 million, up 8.29% from the prior year.
• Common Equity came in at -$216.4 million for Q1 2026 at ADC Therapeutics, down from -$185.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $79.5 million in Q4 2022 to a low of -$238.2 million in Q1 2025.
• The 5-year median for Common Equity is -$178.9 million (2024), against an average of -$135.9 million.
• Across the five-year window, Common Equity sank 784.15% in 2024 and grew 9.17% in 2026, its largest moves.
• ADC Therapeutics' Common Equity stood at $79.5 million in 2022, then sank by 286.59% to -$148.2 million in 2023, then plunged by 36.69% to -$202.6 million in 2024, then grew by 8.29% to -$185.8 million in 2025, then retreated by 16.44% to -$216.4 million in 2026.
• The last three Common Equity figures came in at -$216.4 million (Q1 2026), -$185.8 million (Q4 2025), and -$238.2 million (Q3 2025), per Business Quant data.